05/10/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Bladder Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Bladder Cancer. These NCCN Guidelines^® are currently available as Version 3.2017. 

• Principles of Systemic Therapy
  • First-line chemotherapy for locally advanced or metastatic disease
    • For cisplatin ineligible, “Atezolizumab” was added as a standard option with a category 2A designation for:
      • Bladder cancer
      • Upper GU tract tumors: Renal pelvis 
      • Upper GU tract tumors: Urothelial carcinoma of the ureter 
      • Urothelial carcinoma of the prostate 
      • Primary carcinoma of the urethra (urothelial carcinomas only)
  • Subsequent systemic therapy for locally advanced or metastatic disease
    • “Pembrolizumab” was added as a standard regimen option with a category 1 designation for:
      • Bladder cancer
      • Upper GU tract tumors: Renal pelvis 
      • Upper GU tract tumors: Urothelial carcinoma of the ureter 
      • Urothelial carcinoma of the prostate 
      • Primary carcinoma of the urethra (urothelial carcinomas only)
    • “Durvalumab” was added as a standard regimen option with a category 2A designation for:
      • Bladder cancer
      • Upper GU tract tumors: Renal pelvis 
      • Upper GU tract tumors: Urothelial carcinoma of the ureter 
      • Urothelial carcinoma of the prostate 
      • Primary carcinoma of the urethra (urothelial carcinomas only)

*For your reference, the previous update (Version 2.2017) to the NCCN Guidelines for Bladder Cancer, published on February 16, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf